Skip to main content
SpringerLink
Log in

Daptomycin likely cost effective compared with other regimens for MRSA blood infections in the USA

  • Unknown
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Vu M, et al. Exploratory Cost-Effectiveness Analysis for Treatment of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections: Is Linezolid or Daptomycin Favored Over Vancomycin? Clinical Drug Investigation : 8 Sep 2021. Available from: URL: https://doi.org/10.1007/s40261-021-01077-8

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Daptomycin likely cost effective compared with other regimens for MRSA blood infections in the USA. PharmacoEcon Outcomes News 887, 12 (2021). https://doi.org/10.1007/s40274-021-08028-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-021-08028-2

Search

Navigation